Related references
Note: Only part of the references are listed.Phosphorylation of GAP-43 T172 is a molecular marker of growing axons in a wide range of mammals including primates
Masayasu Okada et al.
MOLECULAR BRAIN (2021)
Repurposing of Antimicrobial Agents for Cancer Therapy: What Do We Know?
Christina Pfab et al.
CANCERS (2021)
Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models
Caroline von Achenbach et al.
JOURNAL OF NEUROCHEMISTRY (2020)
Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity
Antje Arnold et al.
NEURO-ONCOLOGY (2020)
Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy
Yu Kanemaru et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model
Nundia Louis et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma
Toshihiko Wakabayashi et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
mTOR Cross-Talk in Cancer and Potential for Combination Therapy
Fabiana Conciatori et al.
CANCERS (2018)
Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug
Yu Dong et al.
ONCOTARGET (2017)
The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma
Hiroaki Miyahara et al.
CANCER LETTERS (2017)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Targeting Notch Signaling and Autophagy Increases Cytotoxicity in Glioblastoma Neurospheres
Manabu Natsumeda et al.
BRAIN PATHOLOGY (2016)
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma
Malak Abedalthagafi et al.
NEURO-ONCOLOGY (2016)
Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells
Yoshihiro Tsukamoto et al.
STEM CELLS (2016)
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
Catherine S. Grasso et al.
NATURE MEDICINE (2015)
Immunohistochemical profiles of IDH1, MGMT and P53: Practical significance for prognostication of patients with diffuse gliomas
Ryosuke Ogura et al.
NEUROPATHOLOGY (2015)
Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma
Emily Padfield et al.
FRONTIERS IN ONCOLOGY (2015)
Azithromycin suppresses CD4+ T-cell activation by direct modulation of mTOR activity
F. Ratzinger et al.
SCIENTIFIC REPORTS (2014)
rnTOR signaling and its roles in normal and abnormal brain development
Nobuyuki Takei et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2014)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
Beatrice Gini et al.
CLINICAL CANCER RESEARCH (2013)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Focused Ultrasound-Induced Blood-Brain Barrier Opening to Enhance Temozolomide Delivery for Glioblastoma Treatment: A Preclinical Study
Kuo-Chen Wei et al.
PLOS ONE (2013)
Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas
Angela J. Sievert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
The effects of temozolomide delivered by prolonged intracerebral microinfusion against the rat brainstem GBM allograft model
Junichi Yoshimura et al.
CHILDS NERVOUS SYSTEM (2012)
Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases
P. Zarogoulidis et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors
Kah Jing Lim et al.
CANCER BIOLOGY & THERAPY (2011)
Regression of recurrent glioblastoma infiltrating the brainstem after convection-enhanced delivery of nimustine hydrochloride Case report
Ryuta Saito et al.
JOURNAL OF NEUROSURGERY-PEDIATRICS (2011)
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
Gautam Prasad et al.
NEURO-ONCOLOGY (2011)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Translational Regulation of Gene Expression during Conditions of Cell Stress
Keith A. Spriggs et al.
MOLECULAR CELL (2010)
mTOR signaling in glioblastoma: lessons learned from bench to bedside
David Akhavan et al.
NEURO-ONCOLOGY (2010)
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Marc Sanson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
Ta-Jen Liu et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163
Rintaro Hashizume et al.
NEURO-ONCOLOGY (2008)
Macrolide antibiotics as immunomodulatory medications: Proposed mechanisms of action
Masaharu Shinkai et al.
PHARMACOLOGY & THERAPEUTICS (2008)
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Frank B. Furnari et al.
GENES & DEVELOPMENT (2007)
Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: Role of Akt and extracellular signal-regulated kinase signaling pathways
Hiroshi Aoki et al.
MOLECULAR PHARMACOLOGY (2007)
Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases
C. Mayer et al.
ONCOGENE (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors
H Takeuchi et al.
CANCER RESEARCH (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Drug repositioning: Identifying and developing new uses for existing drugs
TT Ashburn et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Genetic pathways to glioblastoma:: A population-based study
H Ohgaki et al.
CANCER RESEARCH (2004)
Brain-derived neurotrophic factor enhances neuronal translation by activating multiple initiation processes - Comparison with the effects of insulin
N Takei et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines
N Hirata et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Repair of O6-alkylguanine by alkyltransferases
AE Pegg
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2000)
Share Paper
